Engineered vitamin E-tethered non-immunogenic facial lipopeptide for developing improved siRNA based combination therapy against metastatic breast cancer.

Carboplatin in combination therapy for metastatic breast cancer.

BACKGROUND Anthracycline-based regimens have a limited role in patients with metastatic breast cancer due to cumulative cardiotoxicity and their common use in adjuvant chemotherapy. New nonanthracycline regimens are, therefore, needed for metastatic disease. Single-agent carboplatin is active in patients with previously untreated metastatic breast cancer, producing response rates of 20%-35%. Pr...

Clinicopathological Features of Non-metastatic Triple Negative Breast Cancer

Background: Triple negative breast cancer (TNBC) is reported to be associated with a high risk of recurrence, poor overall survival (OS), and disease-free survival (DFS) rates. This study evaluated the clincopathological features and survival of non-metastatic TNBC women in the capital of Iran compared with other areas of the world. Methods: In a retrospective study, 119 women with TNBC based ...

Capecitabine-based combination therapy for breast cancer: implications for nurses.

PURPOSE/OBJECTIVES To review available data and implications for nurses of combination regimens containing capecitabine for metastatic breast cancer. DATA SOURCES Peer-reviewed publications or abstracts from major oncology conferences and reviews of capecitabine focusing on nursing implications. DATA SYNTHESIS Capecitabine has proven efficacy in combination with docetaxel and is under evalu...

HER2-directed therapy for metastatic breast cancer.

Human epidermal growth factor receptor 2 (HER2) overexpression drives the biology of 20% of breast cancers, and predicts a poor prognosis for patients. HER2-targeted therapies significantly improve outcomes for HER2-positive patients with both early and metastatic breast cancer. Currently three HER2-targeted agents, trastuzumab (Herceptin), lapatinib (Tykerb), and pertuzumab (Perjeta), are avai...

Breast Cancer Postanthracycline Therapy for Metastatic Disease